This page summarizes trial-derived R&D investment signals for Alzheimer's Disease using the local Clinical Trials Index pipeline snapshot refreshed on 2026-03-01T18:47:49.0699911. The intent is to track portfolio concentration, sponsor mix, and underrepresented mechanism areas that can inform quarterly planning23.
This section provides a reproducible split of active/recruiting trials versus historical (completed/terminated/withdrawn) studies based on ClinicalTrials.gov status as of the database refresh date.
| Category | Trial Count | Share |
|---|---|---|
| Active/Recruiting | 1,287 | 26.4% |
| Not Yet Recruiting | 257 | 5.3% |
| Recruiting | 750 | 15.4% |
| Active, Not Recruiting | 196 | 4.0% |
| Enrolling by Invitation | 84 | 1.7% |
| Historical | 2,961 | 60.8% |
| Completed | 2,518 | 51.7% |
| Terminated | 322 | 6.6% |
| Withdrawn | 105 | 2.2% |
| Suspended | 12 | 0.2% |
| No Longer Available | 4 | 0.1% |
| Unknown | 622 | 12.8% |
Key Insight: Approximately 26.4% of registered Alzheimer's trials are currently active, while 60.8% have reached a terminal status (completed, terminated, or withdrawn). The 12.8% unknown status category reflects trials with unclear or stale registry entries.
The following table shows trial status updates over the past 12 months (March 2025 – February 2026), based on last update date in ClinicalTrials.gov:
| Month | Total Updates | Active/Recruiting | Historical |
|---|---|---|---|
| 2025-03 | 97 | 62 | 35 |
| 2025-04 | 114 | 54 | 60 |
| 2025-05 | 121 | 79 | 42 |
| 2025-06 | 80 | 49 | 31 |
| 2025-07 | 107 | 66 | 41 |
| 2025-08 | 117 | 74 | 43 |
| 2025-09 | 110 | 61 | 49 |
| 2025-10 | 96 | 66 | 30 |
| 2025-11 | 97 | 68 | 29 |
| 2025-12 | 126 | 83 | 43 |
| 2026-01 | 141 | 101 | 40 |
| 2026-02 | 184 | 142 | 42 |
Key Insight: Trial activity has shown an upward trend over the past 12 months, with February 2026 recording the highest number of updates (184). Active/recruiting trials consistently outnumber historical closures, suggesting sustained research investment in Alzheimer's therapeutic development.
Note on Methodology: This trend uses last_update_date from ClinicalTrials.gov, which reflects when sponsors most recently modified trial records. This may include new registrations, status changes, protocol amendments, or results postings. There is typically a 2-4 week lag between actual events and registry updates, and sponsor-name normalization may affect apparent trends.
| Mechanism Cluster | Trial Count | Share |
|---|---|---|
| Amyloid biology | 80 | 8.2% |
| Mitochondrial biology | 75 | 7.7% |
| Genetic / gene-targeted | 63 | 6.5% |
| Tau biology | 28 | 2.9% |
| Tau aggregation | 28 | 2.9% |
| Metabolic pathways | 20 | 2.1% |
| Neuroinflammation | 13 | 1.3% |
| Immunotherapy | 13 | 1.3% |
Mechanism coverage should be interpreted as a directional signal from registry metadata, not a complete map of all preclinical and translational investment streams17. Repeated low-share clusters should be reviewed with disease experts to separate true therapeutic underinvestment from terminology or tagging artifacts in trial records57.
Sponsor-type mix is used here as a practical funding-distribution proxy when direct spend-by-program data are unavailable in public registries24.
| Sponsor Type | Trial Count | Share |
|---|---|---|
| Academic/Medical | 437 | 45.0% |
| Other | 286 | 29.5% |
| Industry | 184 | 18.9% |
| Public (NIH/Gov) | 55 | 5.7% |
| Foundation/Nonprofit | 9 | 0.9% |
Top sponsors by trial volume:
| Sponsor | Trial Count | Share |
|---|---|---|
| Pfizer | 17 | 1.8% |
| Mayo Clinic | 15 | 1.5% |
| Massachusetts General Hospital | 14 | 1.4% |
| University of California, Los Angeles | 10 | 1.0% |
| VA Office of Research and Development | 10 | 1.0% |
| University of Southern California | 9 | 0.9% |
This landscape is designed for recurring quarterly updates rather than one-off commentary. Each cycle should include a refresh of trial records, a rerun of sponsor-type and mechanism-gap summaries, and a brief adjudication of whether the observed distribution reflects true scientific opportunity or only metadata coverage effects in public registries27. Where possible, this page should be interpreted together with detailed pages in Clinical Trials Index, disease pages, and mechanism pages to avoid over-indexing on simple count-based proxies. A practical update checklist is: refresh source data, inspect outliers, verify cross-links, and then publish changes with timestamped reports for reproducibility.
In addition, each update should capture notable shifts in sponsor participation, trial endpoint strategy, and late-stage progression rates so that recurring snapshots can be compared over time rather than read in isolation17.
This page should be used as a decision-support layer rather than a stand-alone funding scoreboard. Trial counts can underestimate preclinical and platform investments that are not registered in ClinicalTrials.gov, while sponsor-label harmonization can influence how activity appears in aggregate views. For that reason, apparent dips or spikes should trigger manual review of underlying trial records, disease-page context, and mechanism-page evidence before major reprioritization decisions are made.
A practical governance pattern is to pair this investment snapshot with a quarterly triage review: confirm which mechanisms are progressing into later-stage studies, identify disease segments where biomarker-qualified endpoints remain sparse, and explicitly document whether observed gaps reflect scientific opportunity or only data-coverage artifacts25. That workflow keeps recommendations traceable, repeatable, and aligned with translational impact goals67.
The study of Alzheimer'S Disease Investment Landscape has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.